Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6774
Gene Symbol: STAT3
STAT3
0.010 Biomarker group BEFREE STAT3 phosphorylation and IL-10 expression were associated with the presence of multiple brain lesions (P = 0.004 and P = 0.027, respectively), suggesting that STAT3 activation may enhance the intracranial spread of tumors in PCNSL. 31778838 2020
Entrez Id: 6387
Gene Symbol: CXCL12
CXCL12
0.010 Biomarker group BEFREE Free CXCL12 reduced the size of the ischemic brain lesion. 31605718 2020
Entrez Id: 23411
Gene Symbol: SIRT1
SIRT1
0.010 Biomarker group BEFREE We confirmed this finding for SIRT1 protein expression and were able to localize upregulated SIRT1 in nuclei of NG2<sup>+</sup> or PDGFRα<sup>+</sup> OPCs in demyelinated brain lesions. 30953735 2019
Entrez Id: 2321
Gene Symbol: FLT1
FLT1
0.010 Biomarker group BEFREE The purpose of this study is to evaluate the performance of 18F-FLT-PET/CT in metastatic brain lesions. 30691084 2019
Entrez Id: 9475
Gene Symbol: ROCK2
ROCK2
0.010 Biomarker group BEFREE We investigated a novel ROCK2 selective inhibitor for the ability to reduce brain lesion formation, growth, and maturation. 31446620 2019
Entrez Id: 23523
Gene Symbol: CABIN1
CABIN1
0.010 Biomarker group BEFREE Neurologic symptoms gradually improved with methylprednisolone pulse therapy and total plasma exchange combined with a calcineurin inhibitor; the brain lesions nearly disappeared after decreasing steroid maintenance dosage, and were completely resolved 1 year after the onset of CNS GVHD. 31309419 2019
Entrez Id: 1832
Gene Symbol: DSP
DSP
0.010 GeneticVariation group BEFREE We report here a patient with a novel DSP spectrin region (SR) 6 variant c.1756C>T, p.(His586Tyr), novel features of brain lesions and severe recurrent mucocutaneous herpes simplex virus infections, with a favourable response to ustekinumab. 31037311 2019
Entrez Id: 1434
Gene Symbol: CSE1L
CSE1L
0.010 Biomarker group BEFREE Peri-procedural brain lesions prevention in CAS (3PCAS): Randomized trial comparing CGuard™ stent vs. Wallstent™. 30266356 2019
Entrez Id: 3918
Gene Symbol: LAMC2
LAMC2
0.010 Biomarker group BEFREE Children with ADS MOG+ and macaques with EAE induced with rhMOG, present a similar cytokine signature in the CSF and a comparable aspect of brain lesions indicating analogous pathophysiological processes. 31785610 2019
Entrez Id: 84650
Gene Symbol: EBPL
EBPL
0.010 Biomarker group BEFREE Analysis of patients' data revealed that (1) a significant N400 component could be detected in 64% (9 of 14 patients) of the DoC patients regardless of the type of DoC; (2) no significant N400 ERP component was retrospectively detected in those E-MCS patients who showed aphasia at the follow-up; and (3) the presence/absence of the N400-ERP component was consistent with the brain lesion side and significantly predict the recovery. 31119978 2019
Entrez Id: 214
Gene Symbol: ALCAM
ALCAM
0.010 Biomarker group BEFREE Last, we determined that the proportion of ALCAM<sup>+</sup> B lymphocytes was increased in the peripheral blood and within brain lesions of patients with MS. Our findings indicate that restricting access to the CNS by targeting ALCAM on pathogenic B lymphocytes might represent a promising strategy for the development of next-generation B lymphocyte-targeting therapies for the treatment of MS. 31723036 2019
Entrez Id: 9564
Gene Symbol: BCAR1
BCAR1
0.010 Biomarker group BEFREE Peri-procedural brain lesions prevention in CAS (3PCAS): Randomized trial comparing CGuard™ stent vs. Wallstent™. 30266356 2019
Entrez Id: 1500
Gene Symbol: CTNND1
CTNND1
0.010 Biomarker group BEFREE Peri-procedural brain lesions prevention in CAS (3PCAS): Randomized trial comparing CGuard™ stent vs. Wallstent™. 30266356 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.010 Biomarker group BEFREE This paper will provide a comparison of classical endpoints like stroke and mortality versus biochemical (non-STEMI) myocardial infarction and DW-MRI new brain lesions and will discuss the importance of cranial nerve lesion in CEA. 30827085 2019
Entrez Id: 1234
Gene Symbol: CCR5
CCR5
0.010 Biomarker group BEFREE Blockade of CCL5 signaling via C-C chemokine receptor type 5 prevented the formation of brain lesions in a mouse model of autoimmune disease. 31243152 2019
Entrez Id: 4908
Gene Symbol: NTF3
NTF3
0.010 AlteredExpression group BEFREE Overexpression of NT3<sup>P75-2</sup> led to a significant reduction in the activation of glial cells, brain water content, and brain lesion volume after TBI. 31651375 2019
Entrez Id: 5054
Gene Symbol: SERPINE1
SERPINE1
0.010 Biomarker group BEFREE PAI-039 reduced brain lesion volume by 26% at 24 hours and 43% at 5 days after insult. 30843275 2019
Entrez Id: 1084
Gene Symbol: CEACAM3
CEACAM3
0.010 Biomarker group BEFREE This paper will provide a comparison of classical endpoints like stroke and mortality versus biochemical (non-STEMI) myocardial infarction and DW-MRI new brain lesions and will discuss the importance of cranial nerve lesion in CEA. 30827085 2019
Entrez Id: 931
Gene Symbol: MS4A1
MS4A1
0.010 Biomarker group BEFREE B cell depletion through anti-CD20 monoclonal antibody utilization and other immunomodulatory therapies have been promising in reducing episodes of relapse and slowing progression, further strengthening the concept that B cells and antibodies are significant players in formation of brain lesions in MS. 31577986 2019
Entrez Id: 10673
Gene Symbol: TNFSF13B
TNFSF13B
0.010 AlteredExpression group BEFREE In this prospective study, we analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. 31615554 2019
Entrez Id: 4311
Gene Symbol: MME
MME
0.010 Biomarker group BEFREE Features associated with a prolonged OS were an ECOG score ≤ 2 (p = 0.001), multiple brain lesions (p = 0.010), multiple area of brain involvement (p = 0.023), MTD < 5 cm (p = 0.004), GCB subtype (p = 0.003) and positive CD10 staining (p = 0.007). 31189479 2019
Entrez Id: 2004
Gene Symbol: ELK3
ELK3
0.010 Biomarker group BEFREE Analysis of patients' data revealed that (1) a significant N400 component could be detected in 64% (9 of 14 patients) of the DoC patients regardless of the type of DoC; (2) no significant N400 ERP component was retrospectively detected in those E-MCS patients who showed aphasia at the follow-up; and (3) the presence/absence of the N400-ERP component was consistent with the brain lesion side and significantly predict the recovery. 31119978 2019
Entrez Id: 6009
Gene Symbol: RHEB
RHEB
0.010 GeneticVariation group BEFREE This RHEB mutation carrier had a dramatic increase of ribosomal protein S6 phosphorylation, indicating mTOR activation in the region of the brain lesion. 31337748 2019
Entrez Id: 7097
Gene Symbol: TLR2
TLR2
0.010 Biomarker group BEFREE Our histopathological analysis showed that the TLR2+/+ and TLR2-/- mice had similar brain lesions at 30 days post infection (dpi) with T. gondii. 31404078 2019
Entrez Id: 100528016
Gene Symbol: TMX2-CTNND1
TMX2-CTNND1
0.010 Biomarker group BEFREE Peri-procedural brain lesions prevention in CAS (3PCAS): Randomized trial comparing CGuard™ stent vs. Wallstent™. 30266356 2019